AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02103023
Drug: Aqueous cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aqueous cream
Trial: NCT04152083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection for IV administration
Trial: NCT01001520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period.
Trial: NCT04061278
Drug: 4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy
Trial: NCT04026230
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar capsules as in the atorvastatin arm, but without the active ingredient
Trial: NCT03549598
Drug: 13NH3 PET/CT scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
Trial: NCT01300247
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m\^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
Trial: NCT01858207
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
Trial: NCT04202965
Drug: PTG-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with PTG-300 injected subcutaneously.
Trial: NCT00525473
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azathioprine usual dosage 100mg per day
Trial: NCT00718094
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet: placebo
Trial: NCT03909737
Drug: Azithromycin to pregnant women
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin to pregnant women at antenatal care visits and during delivery
Trial: NCT03909737
Drug: Azithromycin to infants
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin to infants at 6 and 14 week EPI visits
Trial: NCT03139136
Drug: MBS2320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As described in the arm descriptions
Trial: NCT03139136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As described in the arm descriptions
Trial: NCT03079167
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00321906
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azathioprine 2mg/kg
Trial: NCT02811991
Drug: Morhpine PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose\<25mg/4h.
Trial: NCT04642482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
Trial: NCT01625442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets received daily for 45 days
Trial: NCT03850834
Drug: placebo enteric-coated tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
Trial: NCT02383901
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
Trial: NCT02105285
Drug: OPC-1085EL ophthalmic solution
RxNorm normalized name: Opcon-A Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00672607
Drug: extracts of Vitex agnus castus tablets
RxNorm normalized name: Vitex agnus-castus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
Trial: NCT00672607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00004067
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV every 21 days for 4 cycles
Trial: NCT01899820
Drug: Artemether lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether 20mg Lumefantrine 120mg
Trial: NCT00640419
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
Trial: NCT00640419
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
Trial: NCT01643447
Drug: Diammonium glycyrrhizinate
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02472886
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT01406314
Drug: GSK2315698
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion for approximately 48hours followed by subcutaneous injection
Trial: NCT01051817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion
Trial: NCT02077309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04808934
Drug: VKAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults receiving VKA
Trial: NCT03155347
Drug: Placebo Matched to MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to MTX.
Trial: NCT01821274
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
Trial: NCT01821274
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
Trial: NCT01800799
Drug: Baktar 800mg h.s.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial agent (Baktar 800mg h.s.)
Trial: NCT01800799
Drug: Celecoxib 200mg QD
RxNorm normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory agent (Celecoxib 200mg QD)
Trial: NCT01486823
Drug: MLDL1278A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
Trial: NCT01486823
Drug: MLDL1278A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous dose of 360 mg MLDL1278A.
Trial: NCT03635437
Drug: Gamma-Aminobutyric Acid (GABA)
RxNorm normalized name: GAMMA-AMINOBUTYRIC ACID (GABA) CAP/TAB
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
Trial: NCT00355134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules for oral administration.
Trial: NCT01613183
Drug: Chinese herbal Medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
Trial: NCT03790865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injection
Trial: NCT01634308
Drug: Bio-oss
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00990509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
Trial: NCT02581033
Drug: Nucleoside Analogue therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
Trial: NCT03698305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT02176512
Drug: BIBR 277 SE and HCTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A - fixed dose combination
Trial: NCT02176512
Drug: BIBR 277 SE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B - Monocomponent
Trial: NCT02532283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered placebo tablets orally twice daily for 7 days.
Trial: NCT02853045
Drug: period with generic then period with drug (trade name)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The list of drugs is detailed in the study description
Trial: NCT02194894
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen will be given for patient for both arms for 14 days
Trial: NCT03518047
Drug: placebo for rizankizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for rizankizumab subcutaneous (SC) infusion
Trial: NCT00255164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Trial: NCT01532102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel manufactured to appear identical to AP611074 5% gel
Trial: NCT03770026
Drug: Saline cervical flushing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.
Trial: NCT00002479
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00627523
Drug: Genotropin (PN-180,307) Somatropin
RxNorm normalized name: somatropin Cartridge [Genotropin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable Genotropin
Trial: NCT00627523
Drug: Control-no treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control-no treatment
Trial: NCT02797795
Drug: NEV801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation
Trial: NCT00208260
Drug: FOLFOX-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
Trial: NCT00208260
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
Trial: NCT03313531
Drug: Treatment with recombinant coagulation factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
Trial: NCT02575378
Drug: Metronimic chemotherapy plus Chinese Traditional Medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
Trial: NCT01563731
Drug: all approved antihypertensive drugs; all approved statins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
Trial: NCT01533961
Drug: SCYX-7158
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01533961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00886366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single doses suspension
Trial: NCT00886366
Drug: AZD6714
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single doses a-d suspension
Trial: NCT00886366
Drug: AZD6714
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single doses d and g suspension
Trial: NCT00279344
Drug: Fentanyl (Matrifen)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03619655
Drug: 18F-NaF PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.
Trial: NCT04508686
Drug: Capecitabine, camrelizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a single-arm study with all patients receiving these two drugs.
Trial: NCT00707057
Drug: Ibuprofen 600 mg Extended-Release Tablets
RxNorm normalized name: ibuprofen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
Trial: NCT00707057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
Trial: NCT01003379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided with exactly the same shape, size and appearance.
Trial: NCT00091468
Drug: Placebo transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
Trial: NCT00780780
Drug: Triamcinolone + Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
Trial: NCT00124891
Drug: GAP-486
RxNorm normalized name: GAP JUNCTION ALPHA-3 PROTEIN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03200561
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 2mg/Kg/day for 5 days
Trial: NCT02608996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For comparison to elucidate the true effect of nesiritide
Trial: NCT00841945
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin 50 mg / m² iv day 1 of each course
Trial: NCT03924596
Drug: AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)
RxNorm normalized name: acetyl tetrapeptide-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma
Trial: NCT03654703
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophophamide
Trial: NCT01401946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00635921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flexible doses from 40 to 200 mg/d during 12 weeks
Trial: NCT02609386
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Method of Administration: Cyclophosphamide is administered once by IV
Trial: NCT02609386
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Method of Administration: Indomethacin is administered orally for 21 days.
Trial: NCT04575090
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg daily.
Trial: NCT04186624
Drug: Subacromial-subdeltoid bursa corticosteroid injection
RxNorm normalized name: Capsella bursa-pastoris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
Trial: NCT02858271
Drug: AKB-9778 subcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00148499
Drug: benzocaine
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00459771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 32 mg, oral QD
Trial: NCT00002692
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002692
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002692
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03464084
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing microcrystalline cellulose
Trial: NCT04391179
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given for 14 days while in the hospital.
Trial: NCT04553081
Drug: Dual versus triple therapy in treatment of HIV-1 infection.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cfr arm description
Trial: NCT04033406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% NaCl) given by intramuscular injection
Trial: NCT00536510
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization.
Trial: NCT01033630
Drug: D&G 2g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
Trial: NCT01033630
Drug: D&G 1g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
Trial: NCT01033630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Image-matched placebo, made with starch.
Trial: NCT00699023
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo